SANTA CLARA, Calif. & DURHAM, N.C.--(BUSINESS WIRE)--Jan. 9, 2006--Affymetrix Inc. (Nasdaq:AFFX) announced today that it has entered into a five-year collaboration with Duke University to analyze genomic information across large patient samples. Under terms of the agreement, Duke researchers will use Affymetrix GeneChip(R) microarray technology to develop new applications for translational research projects. The initial projects will focus on cancer and cardiovascular disease.
